☆ 4.8 Meeting Abstract

Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.

CANCER RESEARCH (2021)

Journal

CANCER RESEARCH

Volume 81, Issue 13, Pages -

Publisher

AMER ASSOC CANCER RESEARCH

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.

Journal

CANCER RESEARCH

Publisher

AMER ASSOC CANCER RESEARCH

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.

Journal

CANCER RESEARCH

Publisher

AMER ASSOC CANCER RESEARCH

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper